Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies

Clinical Pharmacokinetics ◽

10.1007/s40262-020-00867-1 ◽

2020 ◽

Vol 59 (6) ◽

pp. 699-714 ◽

Author(s):

Mohamed Elmeliegy ◽

Manoli Vourvahis ◽

Cen Guo ◽

Diane D. Wang

Keyword(s):

Drug Interaction ◽

Glycoprotein P ◽

P Glycoprotein ◽

Interaction Studies ◽

Drug Drug Interaction ◽

Download Full-text

DRUG-DRUG INTERACTION STUDIES OF CARDIOVASCULAR DRUGS (AMIODARONE, DIGOXIN, QUINIDINE, ATORVASTATIN AND VERAPAMIL) INVOLVING P-GLYCOPROTEIN (P-GP), AN EFFLUX TRANSPORTER, ON THE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF EDOXABAN, AN ORAL FACTOR XA INHIBITOR

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(11)61510-6 ◽

2011 ◽

Vol 57 (14) ◽

pp. E1510 ◽

Author(s):

Jeanne Mendell ◽

Halim Zahir ◽

Graham Ridout ◽

Robert Noveck ◽

Frank Lee ◽

...

Keyword(s):

Drug Interaction ◽

Factor Xa ◽

Cardiovascular Drugs ◽

Factor Xa Inhibitor ◽

Efflux Transporter ◽

Glycoprotein P ◽

P Glycoprotein ◽

Interaction Studies ◽

Drug Drug Interaction

Download Full-text

Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects

Clinical Drug Investigation ◽

10.1007/s40261-020-00902-w ◽

2020 ◽

Vol 40 (6) ◽

pp. 529-540

Author(s):

Kazuya Fukumura ◽

Nao Kawaguchi ◽

Toru Ishibashi ◽

Ryuji Kubota ◽

Yukio Tada ◽

...

Keyword(s):

Drug Interaction ◽

Healthy Subjects ◽

P Glycoprotein ◽

Interaction Studies ◽

Drug Drug Interaction ◽

Download Full-text

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

American Journal of Cardiovascular Drugs ◽

10.1007/s40256-013-0029-0 ◽

2013 ◽

Vol 13 (5) ◽

pp. 331-342 ◽

Author(s):

Jeanne Mendell ◽

Hamim Zahir ◽

Nobuko Matsushima ◽

Robert Noveck ◽

Frank Lee ◽

...

Keyword(s):

Drug Interaction ◽

Factor Xa ◽

Cardiovascular Drugs ◽

Factor Xa Inhibitor ◽

Efflux Transporter ◽

P Glycoprotein ◽

Interaction Studies ◽

Drug Drug Interaction

Download Full-text

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

CPT Pharmacometrics & Systems Pharmacology ◽

10.1002/psp4.12449 ◽

2019 ◽

Vol 8 (9) ◽

pp. 685-695 ◽

Author(s):

Yuan Chen ◽

Tamara D. Cabalu ◽

Ernesto Callegari ◽

Heidi Einolf ◽

Lichuan Liu ◽

...

Keyword(s):

Drug Interaction ◽

Pharmacokinetic Model ◽

Physiologically Based Pharmacokinetic Model ◽

Physiologically Based Pharmacokinetic ◽

Interaction Studies ◽

Physiologically Based ◽

Drug Drug Interaction ◽

Download Full-text

Clinical Drug-Drug Interaction Studies: Methods, Pitfalls, and Interpretation

Clinical Therapeutics ◽

10.1016/j.clinthera.2016.07.014 ◽

2016 ◽

Vol 38 (10) ◽

pp. e1-e2

Author(s):

J.T. Backman

Keyword(s):

Drug Interaction ◽

Interaction Studies ◽

Drug Drug Interaction ◽

Download Full-text

Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein

The Journal of Clinical Pharmacology ◽

10.1002/jcph.377 ◽

2014 ◽

Vol 55 (1) ◽

pp. 56-62 ◽

Author(s):

Sarah M. Robertson ◽

Xia Luo ◽

Neeraj Dubey ◽

Chonghua Li ◽

Ajit B. Chavan ◽

...

Keyword(s):

Cytochrome P450 ◽

Drug Interaction ◽

Potential Inhibitor ◽

P Glycoprotein ◽

Drug Drug Interaction ◽

Download Full-text

A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-016-3020-z ◽

2016 ◽

Vol 78 (1) ◽

pp. 41-49 ◽

Author(s):

Vikram Malhi ◽

Dawn Colburn ◽

Sarah J. Williams ◽

Cornelis E. C. A. Hop ◽

Mark J. Dresser ◽

...

Keyword(s):

Drug Interaction ◽

Proton Pump Inhibitor ◽

Proton Pump ◽

Interaction Study ◽

Drug Interaction Study ◽

P Glycoprotein ◽

Cytochrome 450 ◽

Drug Drug Interaction ◽

Download Full-text

Are We Getting the Best Return on Investment From Clinical Drug-Drug Interaction Studies?

The Journal of Clinical Pharmacology ◽

10.1002/jcph.661 ◽

2015 ◽

Vol 56 (5) ◽

pp. 555-558 ◽

Author(s):

Lawrence J. Lesko ◽

Chakradhar V. Lagishetty

Keyword(s):

Drug Interaction ◽

Return On Investment ◽

Interaction Studies ◽

Drug Drug Interaction ◽

Download Full-text

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

Case Medical Research ◽

10.31525/ct1-nct04008186 ◽

2019 ◽

Author(s):

Keyword(s):

Drug Interaction ◽

Drug Drug Interaction ◽

Download Full-text

Faculty Opinions recommendation of Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718043074.793480891 ◽

2013 ◽

Author(s):

Bruno Stieger

Keyword(s):

Risk Assessment ◽

Drug Interaction ◽

Decision Criteria ◽

Inhibitory Potency ◽

Experimental Systems ◽

P Glycoprotein ◽

Drug Drug Interaction

Download Full-text